University and Industry Perspectives on Repurposing Drugs: Successes, Pitfalls, and Patent Opportunities
University and Industry Perspectives on Repurposing Drugs: Successes, Pitfalls, and Patent Opportunities
Join INVO for a presentation about the opportunities and challenges related to the commercialization of repurposed drugs.
Presenters:
Mike Moore
Director of Licensing and Life Sciences
John Haugen
Associate General Counsel
Drug repurposing is the application of already tested or approved drugs and compounds for new indications. This area saw a spike in popularity in the 1990's and 2000s with the success of drugs such as Viagra, Thalidomide, and Botox and is currently reemerging as a big opportunity highlighted by renewed interest from the NIH National Center for Advancing Translation Sciences (NCATS), patient foundations, industry and investors. In this session an overview of the patent, regulatory and other commercial considerations will be presented, alongside recent University/Industry success stories in this field.
This seminar focuses on the opportunities and challenges related to the commercialization of repurposed drugs. Michael Moore will first share a background on patents and the types of inventions that INVO has managed in this space, many of which have been generated by Feinberg researchers. John Haugen will then share his insight on strategies employed by universities and the pharmaceutical industry to capture additional intellectual property protection for drugs that are already known or on the market.
Space is limited, so be sure to reserve a spot. Please use your Northwestern email when registering.
Pizza will be served.
Mike Moore, PhD
Mike came to INVO in 2004. His first and continued responsibility focuses on those inventors and inventions from the Feinberg School of Medicine, as well as select projects from chemistry and engineering faculty.
As Director of Licensing and Life Sciences, Mike's oversees a team of talented colleagues tasked with managing inventions with a life science/medical focus. This includes therapeutics, medical devices, diagnostics, health IT, and research tools. Additionally he oversees licensing efforts for the office beyond the life sciences.
Mike has a B.S. in Biochemistry from the University of Illinois, Urbana-Champaign, and a M.S. and Ph.D. in Biochemistry from the University of California, San Diego.
John Haugen, JD
John joined Northwestern University in 2017 as Associate General Counsel. He is an embedded attorney with Northwestern’s Innovation and New Ventures Office where he advises primarily on Intellectual Property and licensing matters.
Prior to joining Northwestern, John was Senior Counsel of IP at Takeda Pharmaceuticals, USA. At Takeda, he supported IP aspects of business development including due diligence and transactional/agreement work involving acquisitions, spin-outs, in- and out-licenses, divestitures, and research collaborations. His Takeda practice further included marketed product support, Hatch-Waxman litigation, and management of patent prosecution. Before joining Takeda, John was an attorney in private practice in Chicago at the IP law firm Brinks, Hofer, Gilson & Lione working predominantly on patent counseling, prosecution, and litigation.
John received his BS in chemistry from Saint Louis University and JD from Washington University in St. Louis. He is licensed to practice law in Illinois and is a registered patent attorney with the United States Patent and Trademark Office.
Have questions about INVO Series in Evanston | Perspectives on Repurposed Drugs? Contact Innovation and New Ventures (INVO) at Northwestern University
Categories: STEM